Bristol-Myers Squibb Company BMY NYSE

Bristol-Myers Squibb Company (BMY) generated $14.16B in operating cash flow for fiscal year 2025. After capital expenditures of $1.31B, free cash flow was $12.85B.

Free cash flow margin was 26.7% of revenue. Cash conversion ratio was 2.01x, indicating earnings are backed by cash.

The company returned $5.05B in dividends to shareholders during the period.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (75/100, Pass) — $12.85B (26.7% FCF margin) supports a durable competitive advantage
• INCOME (55/100) — Cash conversion ratio was 2.01x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 56/100 with 2/7 criteria passed.